TBC1D13: A Drug Target / Disease Biomarker (G54662)

Target Name: TBC1D13

NCBI ID: G54662

TBC1D13

TBC1D13: A Drug Target / Disease Biomarker

TBC1D13 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the TBC1 family of proteins, which are known for their role in regulating gene expression and cell signaling. TBC1D13 has been identified as a potential drug target due to its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The TBC1 family of proteins was identified through a combination of genetic and biochemical studies. The protein encoded by the TBC1D13 gene is composed of 1,942 amino acids and has a calculated molecular mass of 21.4 kDa. It is expressed in a variety of tissues, including the brain, heart, and kidneys, and is involved in several signaling pathways.

One of the most significant functions of TBC1D13 is its role in cell signaling. The protein is involved in the regulation of several intracellular signaling pathways, including the TGF-β pathway, the Wnt pathway, and the Hedgehog pathway. TBC1D13 has been shown to play a role in the regulation of stem cell proliferation and differentiation, and is also involved in the regulation of tissue repair and regeneration.

In addition to its role in cell signaling, TBC1D13 is also involved in the regulation of gene expression. The protein has been shown to interact with several transcription factors, including NF-kappa-B, AP-1, and STAT3. It is also known to play a role in the regulation of microRNA (miRNA) expression, which are small non-coding RNAs that play a critical role in post-transcriptional gene regulation.

The potential drug target status of TBC1D13 is due to its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. TBC1D13 has been shown to be involved in the development and progression of several types of cancer, including breast, ovarian, and prostate cancer. The protein has also been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its involvement in cancer and neurodegenerative diseases, TBC1D13 is also involved in the regulation of autoimmune disorders. The protein has been shown to play a role in the regulation of immune cell function and has been implicated in the development of autoimmune disorders such as rheumatoid arthritis and multiple sclerosis.

The potential drug target status of TBC1D13 is due to its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The protein has been shown to play a critical role in the regulation of cell signaling and gene expression, and is therefore an attractive target for drug development. Further research is needed to fully understand the function of TBC1D13 and its potential as a drug target.

Protein Name: TBC1 Domain Family Member 13

Functions: Acts as a GTPase-activating protein for RAB35. Together with RAB35 may be involved in regulation of insulin-induced glucose transporter SLC2A4/GLUT4 translocation to the plasma membrane in adipocytes

The "TBC1D13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBC1D13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets